For the quarter ended June 2024, 10x Genomics (TXG) reported revenue of $153.1 million, up 4.3% over the same period last year. EPS came in at -$0.32, compared to -$0.53 in the year-ago quarter. The reported revenue represents a surprise of +1.46% over the Zacks Consensus Estimate of $150.9 million. With the consensus EPS estimate being -$0.47, the EPS surprise was +31.91%. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine ...

10x Genomics (TXG) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.53 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 31.91%. A quarter ago, it was expected that this life science technology company would post a loss of $0.46 per share when it actually produced a loss of $0.50, delivering a surprise of -8.70%. Over the last four quarters, th ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ FORM 10-Q _____________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-39035 | --- | --- | |--------------------- ...

Exhibit 99.1 10x Genomics Reports Second Quarter 2024 Financial Results Recent Highlights Second Quarter 2024 Financial Results 2024 Financial Guidance Webcast and Conference Call Information PLEASANTON, Calif. August 8, 2024 – 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the second quarter ended June 30, 2024. • Revenue was $153.1 million for the second quarter, a 4% increase over the corresponding period of 2023, primarily driven by st ...

PLEASANTON, Calif., Aug. 8, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today several changes to its executive team. Mennah Moustafa has been named Chief Commercial Officer, effective August 1. In this role, Moustafa will be responsible for driving commercial strategy and execution and leading the company's sales, support and marketing functions. Justin McAnear, Chief Financial Officer, will resign from the company effective August 30, to joi ...

PLEASANTON, Calif. , Aug. 8, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the second quarter ended June 30, 2024. Recent Highlights Revenue was $153.1 million for the second quarter, a 4% increase over the corresponding period of 2023, primarily driven by stronger contributions from consumables. Began shipping Xenium Prime 5K, which measures 5,000 genes and features an enhanced chemistry to deliver excellent per-gene ...

● . ● Torex Gold Reports Q2 2024 Results Another consistent quarter of safe and reliable production; on track to deliver on full-year operational guidance August 07, 2024 6:00 PM EDT | Source: Torex Gold Resources Inc. (All amounts expressed in U.S. dollars unless otherwise stated) Toronto, Ontario--(Newsfile Corp. - August 7, 2024) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) reports the Company's financial and operational results for the three and six months ended June 30, 2024. Torex ...

In its upcoming report, 10x Genomics (TXG) is predicted by Wall Street analysts to post quarterly loss of $0.47 per share, reflecting an increase of 11.3% compared to the same period last year. Revenues are forecasted to be $150.9 million, representing a year-over-year increase of 2.8%. The consensus EPS estimate for the quarter has undergone an upward revision of 0.2% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial ...

Wall Street expects a year-over-year increase in earnings on higher revenues when 10x Genomics (TXG) reports results for the quarter ended June 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates. The earnings report, which is expected to be released on August 8, 2024, might help the stock move higher if these key numbers are better than expec ...

● Torex Gold Provides Q2 2024 Update on Media Luna Project (All amounts expressed in U.S. dollars unless otherwise stated) "Development of Media Luna continues to track to schedule, with first production of copper concentrate anticipated by year end and commercial production expected in Q1 2025. As at the end of June, Media Luna was 78% complete across engineering, procurement, underground development/construction, and surface construction, compared to 69% at the end of March. "With completion of Media Luna ...